How does tigecycline's anaerobe coverage differ from metronidazole?

Key differences in anaerobe coverage

- What each covers
- Metronidazole: Very strong, targeted activity against anaerobic bacteria and certain protozoa. It does not cover aerobes or facultative Gram-positive/negative bacteria.
- Tigecycline: Broad-spectrum, including many anaerobes (e.g., the Bacteroides fragilis group and anaerobic cocci) plus a wide range of Gram-positive and many Gram-negative bacteria (except Pseudomonas; activity against some resistant Enterobacteriaceae and MRSA/VRE is possible but not universal). Its anaerobe activity is part of its overall broad coverage.

- Practical difference
- Metronidazole is usually used specifically for anaerobic or protozoal infections (often in combination with another agent to cover aerobes).
- Tigecycline is used when a single agent is desired to cover both anaerobes and resistant Gram-positive/Gram-negative pathogens (excluding Pseudomonas), i.e., for mixed or complicated infections.

- Protozoa vs bacteria
- Metronidazole also treats protozoal infections (e.g., Giardia, Entamoeba, Trichomonas).
- Tigecycline has no activity against protozoa.

- Important caveats
- Neither drug covers Pseudomonas; tigecycline has variable activity against other non-fermenters and some resistant Gram-negatives.
- If the goal is pure anaerobic coverage, metronidazole is typically preferred. If the infection likely involves resistant Gram-positives and Gram-negatives in addition to anaerobes, tigecycline may be considered (with caution about its safety profile and guidelines).

If you want, I can tailor this to a specific infection scenario (e.g., intra-abdominal, gynecologic, skin/soft tissue).